ARTICLE | Clinical News
Norastemizole: Filed an IND with the FDA to begin a series of fast-track Phase II trials
January 15, 1996 8:00 AM UTC
Sepracor Inc. (SEPR), Marlborough, Mass. Product: Norastemizole, active metabolite of Janssen's Hismanal (astemizole) antihistamine Indication: Allergy Status: Filed an IND with the FDA to begin a ser...